Protalix Operating Cycle from 2010 to 2024

PLX Stock  USD 1.69  0.01  0.60%   
Protalix Biotherapeutics Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 315.26 in 2024. During the period from 2010 to 2024, Protalix Biotherapeutics Operating Cycle regression line of annual values had r-squared of  0.0007 and arithmetic mean of  477.78. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
331.85359924
Current Value
315.26
Quarterly Volatility
680.08911626
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Selling General Administrative of 26.7 M or Other Operating Expenses of 31.5 M, as well as many indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 3.4. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Protalix Biotherapeutics over the last few years. It is Protalix Biotherapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Very volatile
   Operating Cycle   
       Timeline  

Protalix Operating Cycle Regression Statistics

Arithmetic Mean477.78
Geometric Mean305.64
Coefficient Of Variation142.34
Mean Deviation337.24
Median315.26
Standard Deviation680.09
Sample Variance462,521
Range2.8K
R-Value(0.03)
Mean Square Error497,749
R-Squared0.0007
Significance0.93
Slope(4.03)
Total Sum of Squares6.5M

Protalix Operating Cycle History

2024 315.26
2023 331.85
2022 348.2
2021 433.59
2020 450.76
2019 304.57
2018 386.65

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 331.85  315.26 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.